Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases
Patent No. EP3925607 (titled "Pharmaceutical Compositions For The Treatment Of Cystic Fibrosis Transmembrane Conductance Regulator Mediated Diseases") was filed by Vertex Pharmaceuticals Incorporated on Apr 14, 2015. The application was issued on Jul 16, 2025.
Patent Summary
A pharmaceutical composition for treating cystic fibrosis comprising a combination of two spray-dried dispersions, each containing an amorphous form of a different active pharmaceutical ingredient (API), and a polymer. The first dispersion contains 70-90 wt% of the API (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and 10-30 wt% of a polymer, while the second dispersion contains 100 wt% of the API N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide. The composition is formulated as a tablet.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3925607
- Application Number
- EP21175519A
- Filing Date
- Apr 14, 2015
- Status
- Granted And Under Opposition
- May 26, 2023
- Publication Date
- Jul 16, 2025
- External Links
- Slate, Register , Google Patents